{"id":"allogenic-human-purified-pancreatic-islets","safety":{"commonSideEffects":[{"rate":null,"effect":"Graft rejection"},{"rate":null,"effect":"Immunosuppression-related infections"},{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Bleeding at transplant site"}]},"_chembl":{"chemblId":"CHEMBL4299330","moleculeType":"Unknown","molecularWeight":"4182.77"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This therapy involves isolation and purification of insulin-secreting islet cells from deceased human donors, which are then transplanted into patients with type 1 diabetes to restore endogenous insulin production. The transplanted islets engraft in the recipient and begin producing insulin in response to blood glucose levels, reducing or eliminating the need for exogenous insulin therapy. This approach aims to achieve better glycemic control and reduce hypoglycemic episodes compared to insulin injection alone.","oneSentence":"Allogenic human purified pancreatic islets restore insulin-producing beta cell function by transplanting functional islet cells into patients with type 1 diabetes.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:00:56.214Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus with severe hypoglycemia unawareness or brittle diabetes"}]},"trialDetails":[{"nctId":"NCT00434811","phase":"PHASE3","title":"Islet Transplantation in Type 1 Diabetes","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-10","conditions":"Type 1 Diabetes Mellitus","enrollment":48},{"nctId":"NCT00468117","phase":"PHASE3","title":"Efficacy of Islet After Kidney Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2007-01","conditions":"Type 1 Diabetes Mellitus","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Allogenic human purified pancreatic islets","genericName":"Allogenic human purified pancreatic islets","companyName":"National Institute of Allergy and Infectious Diseases (NIAID)","companyId":"national-institute-of-allergy-and-infectious-diseases-niaid","modality":"Biologic","firstApprovalDate":"","aiSummary":"Allogenic human purified pancreatic islets restore insulin-producing beta cell function by transplanting functional islet cells into patients with type 1 diabetes. Used for Type 1 diabetes mellitus with severe hypoglycemia unawareness or brittle diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}